Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 oct. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma

MADISON, Wis., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces the design of...
17 oct. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors

MADISON, Wis., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese...
12 oct. 2017 11h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering

MADISON, Wis., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) ("Cellectar" or the "Company"), an oncology-focused biotechnology company, today announces the closing of...
10 oct. 2017 13h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market

MADISON, Wis., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “Company”), an oncology-focused biotechnology company, today announced that it entered...
10 oct. 2017 07h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates

MADISON, Wis. and CASTRES, France, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), together...
29 sept. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at The MicroCap Conference

MADISON, Wis., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), today announced that president and CEO Jim...
27 sept. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131

MADISON, Wis., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that a patient...
21 sept. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates

MADISON, Wis., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), and Onconova Therapeutics...
20 sept. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference

MADISON, Wis., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), today announced that president and CEO Jim...
18 sept. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer

MADISON, Wis., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the “company”), announced that effective today Jarrod Longcor,...

Page précédente

Page suivante